Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 12/20 | 0.36 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | FLT1 | P17948 | 3/20 | 0.36 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.32 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415078 | 0.89 | HSPD1 (0.45) | TP53MAPTSMN1; SMN2POLBEGFR | |
| SCHEMBL6415087 | 0.89 | HSPD1 (0.45) | TP53MAPTSMN1; SMN2POLBEGFR | |
| SCHEMBL6431731 | 0.88 | PSD (0.35) | TP53MAPTSMN1; SMN2POLBPSD | |
| SCHEMBL6508198 | 0.88 | PSD (0.35) | TP53MAPTSMN1; SMN2POLBPSD | |
| SCHEMBL6414739 | 0.84 | MAPT (0.40) | TP53MAPTSMN1; SMN2POLBEGFR | |
| SCHEMBL6414730 | 0.84 | MAPT (0.40) | TP53MAPTSMN1; SMN2POLBEGFR | |
| SCHEMBL6432676 | 0.84 | HSPD1 (0.40) | TP53MAPTSMN1; SMN2POLBEGFR | |
| SCHEMBL6432681 | 0.84 | HSPD1 (0.40) | TP53MAPTSMN1; SMN2POLBEGFR | |
| SCHEMBL6415073 | 0.83 | EGFR (0.33) | TP53MAPTSMN1; SMN2POLBEGFR | |
| SCHEMBL6412904 | 0.82 | IDO1 (0.35) | TP53MAPTSMN1; SMN2POLBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | 4SC AG (DE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044270-A1 | OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS | 4SC AG (DE) | 2005-05-19 | — | — | WO | disclosed |
| EP-1529531-A1 | Oxadiazolopyrazine derivatives as pharmaceutically active compounds | 4SC AG (DE) | 2005-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | NR5A2, NR1H2, NR2C2 | TP53 4485/4885MAPT 4420/4885SMN1; SMN2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.